Expert Rev Ophthalmol. 2008;3(4):449-456. Infliximab is a monoclonal human-murine chimeric antibody. Since it is a chimeric antibody, infliximab is usually given concomitantly with a second agent, ...
An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...
Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...
An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...
Medidur is an injectable micro-insert designed to treat posterior uveitis and can be administered to the back of the eye during an office procedure. Uveitis is a noninfectious inflammatory disease ...
An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.
Please provide your email address to receive an email when new articles are posted on . Avoid a “kitchen sink” work-up, instead focusing on history, findings and imaging. Treatment options include ...
Posterior segment non-infectious uveitis (NIPU) is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in ...
Yutiq is supplied as a 0.18mg single-dose, preloaded applicator with a 25-gauge needle. The approval was based on data from 2 sham injection-controlled, double-masked Phase 3 trials. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback